<DOC>
	<DOCNO>NCT02685969</DOCNO>
	<brief_summary>Study understand factor related preclinical stage Alzheimer 's Disease investigate marker predict progression . Cross-sectional single arm study perform subgroup individual recruit ALFA project . Study without therapeutic interest research participant ( 440 participant ALFA project select cognitively healthy vast majority direct descendant patient diagnose Alzheimer 's Disease ) . Each study candidate select ALFA project ( STUDY 45-65 FPM/2012 ) accord clinical characteristic , compliance selection criterion desire participate study . After sign study 's specific informed consent form , neuropsychological screening brain MRI acquisition perform . Once inclusion criterion check , PET scan 18F-Flutemetamol 18F-FDG perform</brief_summary>
	<brief_title>Brain Characterization Amyloid Protein Glucose Metabolism ALFA Project Participants</brief_title>
	<detailed_description>18F‐Flutemetamol scan categorize either positive negative accord standardized uptake value ratio ( quantitative measurement base ratio mean target cortex activity divide cerebellar reference region ) . Participants SUVr 1.56 classified positive , otherwise , negative .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>To sign study informed consent form approve corresponding authority . Men woman enrol ALFA project ( STUDY 45‐65 FPM/2012 ) . Participants cerebral MRI ( magnetic resonance imaging ) suggestive radiological incidental finding constitute exclusion criterion . Cognition within psychometrically normal range : MMSE ( Mini Mental State Examination ≥26 Semantic Fluency ( animal ) ≥12 . Score 0 CDR scale ( Clinical Dementia Rating ) . Good knowledge language literate . Female participant post‐menopausal present negative pregnancy test moment PET acquisition . Present cognitive impairment . Presence clinically relevant psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSM‐IV‐TR ) criterion : major depressive disorder , generalize anxiety disorder , schizophrenia bipolar disorder . Individuals visual and/or hearing impairment . History encephalitis , ictus seizure exclude feverish convulsion childhood . Severe cerebral macrovascular ( i.e. , multi‐stroke ) disease brain tumor ( metastasis/brain cancer ) verify magnetic resonance imaging ( MRI ) . Any contraindication MRI acquisition , ( i.e. , metal implant ) phobia perform scan determine onsite physician . Previous participation clinical study involve investigational pharmaceutical product within 30 day prior screen and/or administration radiopharmaceutical within 10 radioactive half‐lives prior study drug administration study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Positron Emission Tomography</keyword>
</DOC>